Table 1 Summary of the patient sub-cohorts characteristics.
Variable | Control group (N = 50) | EBV+ group (N = 54) | P value | |
|---|---|---|---|---|
Female gender | 13 (26.0%) | 15 (27.8%) | 1.000 | |
Age (years) | 56 (44–62) | 55 (49–63) | 0.530 | |
Donor age (years) | 54 (43–61) | 54 (48–62) | 0.574 | |
Body mass index (kg/m2) | 25.2 (22.8–28.8) | 24.8 (22.7–29.8) | 0.925 | |
Baseline white blood cell count (109 cells/L) | 7.4 (6.2–8.9) | 6.7 (5.6–9.0) | 0.265 | |
Baseline C reactive protein (mg/L) | 2.8 (0.5–5.5) | 1.6 (0.5–3.0) | 0.298 | |
Negative EBV serostatus pre-transplanta | 3 (10.3%) | 1 (3.6%) | 0.611 | |
Therapy arm | Arm A (basiliximab + tacrolimus + MMF + steroids) | 14 (28.0%) | 15 (27.8%) | 0.998 |
Arm B (basiliximab + tacrolimus + MMF + rapid steroid withdrawal) | 9 (18.0%) | 10 (18.5%) | ||
Arm C (rabbit ATG + tacrolimus + MMF + rapid steroid withdrawal) | 27 (54.0%) | 29 (53.7%) | ||
Anti-cytomegalovirus prophylaxis | 27 (54.0%) | 32 (59.3%) | 0.732 | |
Acute rejection incidence | 7 (14.0%) | 8 (14.8%) | 1.000 | |
Cytomegalovirus reactivation incidence | 9 (18.0%) | 13 (24.1%) | 0.605 | |
Glomerular filtration rate 2 weeks post-transplantation (mL/min/1.73 m2) | 31.3 (17.8–43.7) | 29.4 (15.9–47.9) | 0.896 | |
Glomerular filtration rate 1 year post-transplantation (mL/min/1.73 m2) | 46.9 (35.6–64.5) | 47.5 (33.3–58.9) | 0.419 | |
Screening time points (post-transplantation days) | Before | 15 (1–56) | 13 (1–54) | 0.486 |
Peak | 31 (25–92) | 30 (20–91) | 0.623 | |
After | 62 (55–247) | 70 (58–250) | 0.649 | |
